BRAF and RAS (KRAS or NRAS) mCRC PATIENTS. Maybe of the interest of those with p53 deficient or mutated too.
A trial (update:) recruiting at Dec 29th 2016. It's not immunotherapy, but irinotecan plus AZD1775 (a WEE1 inhibitor; "a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity").
Posting because it's an area of high unmet need.
https://clinicaltrials.gov/ct2/show/NCT02906059
It has been at least a Phase I Study Evaluating it Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin (Solid Tumors) http://ascopubs.org/doi/abs/10.1200/JCO.2016.67.5991 and a Phase II study with it plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (< 3 months) to standard first line therapy http://meetinglibrary.asco.org/content/149374-156 More: https://ncats.nih.gov/files/AZD1775.pdf